Related references
Note: Only part of the references are listed.Cerebrospinal Fluid, Plasma, and Saliva in the BioFIND Study: Relationships Among Biomarkers and Parkinson's Disease Features
Jennifer G. Goldman et al.
MOVEMENT DISORDERS (2018)
Evolution of cerebrospinal fluid total alpha-synuclein in Parkinson's disease
Marthe Gurine Forland et al.
PARKINSONISM & RELATED DISORDERS (2018)
Cross-Sectional and Longitudinal Cognitive Correlates of FDDNP PET and CSF Amyloid-β and Tau in Parkinson's Disease
Mariateresa Buongiorno et al.
JOURNAL OF ALZHEIMERS DISEASE (2017)
Expression of prion protein in the cerebrospinal fluid of patients with Parkinson's disease complicated with rapid eye movement sleep behavior disorder
W. J. Zhang et al.
GENETICS AND MOLECULAR RESEARCH (2017)
Protein aggregation and neurodegeneration in prototypical neurodegenerative diseases: Examples of amyloidopathies, tauopathies and synucleinopathies
Mathieu Bourdenx et al.
PROGRESS IN NEUROBIOLOGY (2017)
Non-Amyloid-β Component of Human α-Synuclein Oligomers Induces Formation of New Aβ Oligomers: Insight into the Mechanisms That Link Parkinson's and Alzheimer's Diseases
Yoav Atsmon-Raz et al.
ACS CHEMICAL NEUROSCIENCE (2016)
A LUHMES 3D dopaminergic neuronal model for neurotoxicity testing allowing long-term exposure and cellular resilience analysis
L. Smirnova et al.
ARCHIVES OF TOXICOLOGY (2016)
CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study
Ju-Hee Kang et al.
ACTA NEUROPATHOLOGICA (2016)
High-Accuracy Detection of Early Parkinson's Disease through Multimodal Features and Machine Learning
R. Prashanth et al.
INTERNATIONAL JOURNAL OF MEDICAL INFORMATICS (2016)
α-Synuclein Fibrils Exhibit Gain of Toxic Function, Promoting Tau Aggregation and Inhibiting Microtubule Assembly
Takayuki Oikawa et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2016)
Cerebrospinal fluid total tau concentration predicts clinical phenotype in Huntington's disease
Filipe Brogueira Rodrigues et al.
JOURNAL OF NEUROCHEMISTRY (2016)
Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders
Brit Mollenhauer et al.
JOURNAL OF NEUROCHEMISTRY (2016)
Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson's Disease
Sara Hall et al.
MOVEMENT DISORDERS (2016)
Longitudinal changes in CSF alpha-synuclein species reflect Parkinson's disease progression
Nour K. Majbour et al.
MOVEMENT DISORDERS (2016)
Monitoring of 30 marker candidates in early Parkinson disease as progression markers
Brit Mollenhauer et al.
NEUROLOGY (2016)
Environmental risk factors and Parkinson's disease: An umbrella review of meta-analyses
Vanesa Bellou et al.
PARKINSONISM & RELATED DISORDERS (2016)
Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease
Matthew R. Brier et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Cerebrospinal Fluid Amyloid β1-42, Tau, and Alpha-Synuclein Predict the Heterogeneous Progression of Cognitive Dysfunction in Parkinson's Disease
Ju-Hee Kang
JOURNAL OF MOVEMENT DISORDERS (2016)
Parkinson's disease as a result of aging
Manuel Rodriguez et al.
AGING CELL (2015)
Pathological Interface Between Oligomeric Alpha-Synuclein and Tau in Synucleinopathies
Urmi Sengupta et al.
BIOLOGICAL PSYCHIATRY (2015)
Amyloid deposition in Parkinson's disease and cognitive impairment: A systematic review
Myria Petrou et al.
MOVEMENT DISORDERS (2015)
Do CSF Biomarkers Predict Progression to Cognitive Impairment in Parkinson's disease patients? A Systematic Review
Katherine Leaver et al.
NEUROPSYCHOLOGY REVIEW (2015)
Rapid Eye Movement Sleep Behavior Disorder and Neurodegenerative Disease
Michael Joseph Howell et al.
JAMA NEUROLOGY (2015)
Cerebrospinal Fluid α-Synuclein Predicts Cognitive Decline in Parkinson Disease Progression in the DATATOP Cohort
Tessandra Stewart et al.
AMERICAN JOURNAL OF PATHOLOGY (2014)
Models of β-amyloid induced Tau-pathology: the long and folded road to understand the mechanism
Ilie-Cosmin Stancu et al.
MOLECULAR NEURODEGENERATION (2014)
Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's Disease
Lucilla Parnetti et al.
FRONTIERS IN AGING NEUROSCIENCE (2014)
Parkinson Disease Subtypes
Mary Ann Thenganatt et al.
JAMA NEUROLOGY (2014)
REM Sleep Behavior Disorder (RBD) as a marker of neurodegenerative disorders
L. Ferini-Strambi et al.
ARCHIVES ITALIENNES DE BIOLOGIE (2014)
CSF α-synuclein improves diagnostic and prognostic performance of CSF tau and Aβ in Alzheimer's disease
Jon B. Toledo et al.
ACTA NEUROPATHOLOGICA (2013)
Cerebrospinal fluid biomarkers in Parkinson disease
Lucilla Parnetti et al.
NATURE REVIEWS NEUROLOGY (2013)
Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies
David J. Irwin et al.
NATURE REVIEWS NEUROSCIENCE (2013)
Association of Cerebrospinal Fluid β-Amyloid 1-42, T-tau, P-tau181, and α-Synuclein Levels With Clinical Features of Drug-Naive Patients With Early Parkinson Disease
Ju-Hee Kang et al.
JAMA NEUROLOGY (2013)
Neuropathologic substrates of Parkinson disease dementia
David J. Irwin et al.
ANNALS OF NEUROLOGY (2012)
Accuracy of a Panel of 5 Cerebrospinal Fluid Biomarkers in the Differential Diagnosis of Patients With Dementia and/or Parkinsonian Disorders
Sara Hall et al.
ARCHIVES OF NEUROLOGY (2012)
Exosomal cell-to-cell transmission of alpha synuclein oligomers
Karin M. Danzer et al.
MOLECULAR NEURODEGENERATION (2012)
Neuropathology underlying clinical variability in patients with synucleinopathies
Glenda M. Halliday et al.
ACTA NEUROPATHOLOGICA (2011)
Induction of Intracellular Tau Aggregation Is Promoted by α-Synuclein Seeds and Provides Novel Insights into the Hyperphosphorylation of Tau
Elisa A. Waxman et al.
JOURNAL OF NEUROSCIENCE (2011)
α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study (vol 10, pg 230, 2011)
B. Mollenhauer et al.
LANCET NEUROLOGY (2011)
Cerebrospinal Fluid Tau/α-Synuclein Ratio in Parkinson's Disease and Degenerative Dementias
Lucilla Parnetti et al.
MOVEMENT DISORDERS (2011)
The Parkinson Progression Marker Initiative (PPMI)
Kenneth Marek et al.
PROGRESS IN NEUROBIOLOGY (2011)
α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study
Brit Mollenhauer et al.
LANCET NEUROLOGY (2011)
DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease
Zhen Hong et al.
BRAIN (2010)
CSF amyloid-β and tau proteins, and cognitive performance, in early and untreated Parkinson's Disease: the Norwegian ParkWest study
Guido Alves et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2010)
Synergistic Interactions between Aβ, Tau, and α-Synuclein: Acceleration of Neuropathology and Cognitive Decline
Lani K. Clinton et al.
JOURNAL OF NEUROSCIENCE (2010)
Cell-Produced α-Synuclein Is Secreted in a Calcium-Dependent Manner by Exosomes and Impacts Neuronal Survival
Evangelia Emmanouilidou et al.
JOURNAL OF NEUROSCIENCE (2010)
CSF Aβ42 and tau in Parkinson's Disease with Cognitive Impairment
Thomas J. Montine et al.
MOVEMENT DISORDERS (2010)
Severity of REM atonia loss in idiopathic REM sleep behavior disorder predicts Parkinson disease
R. B. Postuma et al.
NEUROLOGY (2010)
Parkinson Disease With Dementia Comparing Patients With and Without Alzheimer Pathology
Marwan N. Sabbagh et al.
ALZHEIMER DISEASE & ASSOCIATED DISORDERS (2009)
Cerebrospinal Fluid Biomarkers in Parkinson's Disease with Dementia and Dementia with Lewy Bodies
Lucilla Parnetti et al.
BIOLOGICAL PSYCHIATRY (2008)
Direct quantification of CSF α-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration
Brit Mollenhauer et al.
EXPERIMENTAL NEUROLOGY (2008)
Biomarkers for cognitive impairment and dementia in elderly people
Joshua A. Sonnen et al.
LANCET NEUROLOGY (2008)
Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study
O Hansson et al.
LANCET NEUROLOGY (2006)
Share Paper
